文献速递消化道肿瘤与早癌

低剂量阿司匹林使用不增加食管癌或胃癌患者的生存期:两项独立人群队列研究

Low-Dose Aspirin Use Does Not Increase Survival in 2 Independent Population-Based Cohorts of Patients With Esophageal or Gastric Cancer.
PubMed 文献 · Gastroenterology · 2017-11-06

基于英格兰1998至2012年和苏格兰2009至2012年癌症登记处的两项独立人群队列,纳入4654例食管癌和3833例胃癌患者,采用时间依赖Cox回归分析。诊断后低剂量阿司匹林使用与食管癌(汇总校正HR 0.98;95%CI 0.89-1.09)或胃癌(汇总校正HR 0.96;95%CI 0.85-1.08)的癌症特异性死亡率无关,长期使用亦无关联。结论认为低剂量阿司匹林使用不增加食管癌或胃癌患者的生存期。

要点

  • 诊断后低剂量阿司匹林使用与食管癌癌症特异性死亡率无关(汇总校正HR 0.98;95%CI 0.89-1.09)。
  • 诊断后低剂量阿司匹林使用与胃癌癌症特异性死亡率无关(汇总校正HR 0.96;95%CI 0.85-1.08)。
  • 长期阿司匹林使用与食管癌(汇总校正HR 1.03;95%CI 0.85-1.25)或胃癌(汇总校正HR 1.06;95%CI 0.85-1.32)的癌症特异性死亡率无关联。

核心结论

  • 在英国的2项大型独立队列分析中,低剂量阿司匹林使用与食管癌或胃癌患者诊断后生存期延长无关。

研究设计与样本

  • 基于人群的队列研究,使用英格兰1998年至2012年和苏格兰2009年至2012年癌症登记处新诊断的食管癌或胃癌患者。
  • 低剂量阿司匹林处方通过链接英国临床实践研究数据链(英格兰)和处方信息系统(苏格兰)识别。
  • 死亡通过链接国家死亡记录识别,英格兰随访至2015年9月,苏格兰随访至2015年1月。
  • 采用时间依赖Cox回归模型计算校正潜在混杂因素后低剂量阿司匹林使用的癌症特异性死亡率风险比(HR)和95%置信区间(CI),并用Meta分析合并两队列结果。
  • 合并的英格兰和苏格兰队列包含4654例食管癌患者和3833例胃癌患者,分别有3240例和2392例癌症特异性死亡。

主要发现

  • 食管癌诊断后1年生存比例(基于癌症特异性死亡率)在阿司匹林使用者与非使用者中分别为:英格兰48% vs 50%,苏格兰49% vs 46%。
  • 胃癌诊断后1年生存比例(基于癌症特异性死亡率)在阿司匹林使用者与非使用者中分别为:英格兰58% vs 57%,苏格兰59% vs 55%。
  • 诊断后低剂量阿司匹林使用与食管癌癌症特异性死亡率无关(汇总校正HR 0.98;95%CI 0.89-1.09)。
  • 诊断后低剂量阿司匹林使用与胃癌癌症特异性死亡率无关(汇总校正HR 0.96;95%CI 0.85-1.08)。
  • 长期阿司匹林使用与食管癌(汇总校正HR 1.03;95%CI 0.85-1.25)或胃癌(汇总校正HR 1.06;95%CI 0.85-1.32)诊断后癌症特异性死亡率无关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Preclinical studies have shown aspirin to have anticancer properties and epidemiologic studies have associated aspirin use with longer survival times of patients with cancer. We studied 2 large cohorts to determine the association between aspirin use and cancer-specific mortality in patients with esophageal or gastric cancer. METHODS: We performed a population-based study using cohorts of patients newly diagnosed with esophageal or gastric cancer, identified from cancer registries in England from 1998 through 2012 and the Scottish Cancer Registry from 2009 through 2012. Low-dose aspirin prescriptions were identified from linkages to the United Kingdom Clinical Research Practice Datalink in England and the Prescribing Information System in Scotland. Deaths were identified from linkage to national mortality records, with follow-up until September 2015 in England and January 2015 in Scotland. Time-dependent Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer-specific mortality by low-dose aspirin use after adjusting for potential confounders. Meta-analysis was used to pool results across the 2 cohorts. RESULTS: The combined English and Scottish cohorts contained 4654 patients with esophageal cancer and 3833 patients with gastric cancer, including 3240 and 2392 cancer-specific deaths, respectively. The proportions surviving 1 year, based on cancer-specific mortality, were similar in aspirin users vs non-users after diagnosis with esophageal cancer (48% vs 50% in England and 49% vs 46% in Scotland, respectively) or gastric cancer (58% vs 57% in England and 59% vs 55% in Scotland, respectively). There was no association between postdiagnosis use of low-dose aspirin and cancer-specific mortality among patients with esophageal cancer (pooled adjusted HR, 0.98; 95% CI, 0.89-1.09) or gastric cancer (pooled adjusted HR, 0.96; 95% CI, 0.85-1.08). Long-term aspirin use was not associated with cancer-specific mortality after diagnosis of esophageal cancer (pooled adjusted HR, 1.03; 95% CI, 0.85-1.25) or gastric cancer (pooled adjusted HR, 1.06; 95% CI, 0.85-1.32). CONCLUSIONS: In analyses of 2 large independent cohorts in the United Kingdom, low-dose aspirin usage was not associated with increased survival of patients diagnosed with esophageal or gastric cancer.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Spence AD, Busby J, Johnston BT, et al. Low-Dose Aspirin Use Does Not Increase Survival in 2 Independent Population-Based Cohorts of Patients With Esophageal or Gastric Cancer. Gastroenterology. 2017. PMID: 29122547. doi:10.1053/j.gastro.2017.10.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。